Insider trading

Period: 120 months Stock: LLY Plan: Discretionary × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

123 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

123 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

123 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

123 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
123 decisions over 120 months Remove this filter
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
123 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

123 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
6 May 2026
LILLY ENDOWMENT INC Former 10% Shareholder
Sold at will 2×
$15.75M 15,828 at 995.36
0.0%
Not planned
7 Jan 2026
Sold at will 30×
$322.38M 292,148 at 1,103.48
0.3%
Not planned
5 Jan 2026
Sold at will
$1.51M 1,390 at 1,085.01
0.0%
Not planned
29 Dec 2025
Sold at will
$3.90M 3,593 at 1,085.04
0.0%
Not planned
24 Dec 2025
Sold at will
$2.85M 2,629 at 1,085.17
0.0%
Not planned
23 Dec 2025
Sold at will
$260.41K 240 at 1,085.04
0.0%
Not planned
25 Nov 2025
Sold at will 33×
$178.42M 162,693 at 1,096.69
0.2%
Not planned
24 Nov 2025
Sold at will 6×
$152.06M 142,307 at 1,068.52
0.2%
Not planned
21 Nov 2025
Sold at will 17×
$111.50M 105,326 at 1,058.66
0.1%
Not planned
20 Nov 2025
Sold at will 6×
$39.07M 37,148 at 1,051.66
0.0%
Not planned
19 Nov 2025
Sold at will 6×
$176.10M 167,526 at 1,051.17
0.2%
Not planned
18 Nov 2025
Sold at will 10×
$62.31M 60,213 at 1,034.78
0.1%
Not planned
17 Nov 2025
Sold at will 2×
$10.19M 9,886 at 1,030.68
0.0%
Not planned
14 Nov 2025
Sold at will 4×
$75.91B 178,295 at 425,738.48
0.2%
Not planned
13 Nov 2025
Sold at will 2×
$48.02M 46,606 at 1,030.26
0.1%
Not planned
12 Nov 2025
Sold at will 20×
$308.41M 305,000 at 1,011.18
0.3%
Not planned
11 Nov 2025
Sold at will 27×
$279.35M 283,131 at 986.64
0.3%
Not planned
10 Nov 2025
Sold at will 3×
$16.41M 16,869 at 972.52
0.0%
Not planned
5 Nov 2025
Sold at will 38×
$205.57M 219,474 at 936.63
0.2%
Not planned
4 Nov 2025
Sold at will
$479.04K 526 at 910.72
0.0%
Not planned
3 Nov 2025
Sold at will 24×
$266.65M 300,000 at 888.83
0.3%
Not planned
31 Oct 2025
Sold at will 8×
$260.17M 301,342 at 863.35
0.3%
Not planned
10 Oct 2025
Sold at will 2×
$3.16M 3,658 at 863.24
0.0%
Not planned
9 Oct 2025
Sold at will 8×
$9.04M 10,602 at 852.49
0.0%
Not planned
8 Oct 2025
Sold at will 8×
$86.23M 101,420 at 850.27
0.1%
Not planned
7 Oct 2025
Sold at will
$22.72M 26,795 at 848.01
0.0%
Not planned
6 Oct 2025
Sold at will 8×
$137.04M 161,183 at 850.22
0.2%
Not planned
3 Oct 2025
Sold at will 25×
$161.22M 192,404 at 837.93
0.2%
Not planned
2 Oct 2025
Sold at will 9×
$92.50M 112,596 at 821.55
0.1%
Not planned
1 Oct 2025
Sold at will 55×
$284.65M 351,015 at 810.94
0.4%
Not planned
30 Sep 2025
Sold at will 4×
$86.79M 113,694 at 763.39
0.1%
Not planned
19 Sep 2025
Sold at will 2×
$18.06M 23,665 at 763.10
0.0%
Not planned
18 Sep 2025
Sold at will 5×
$81.53M 106,626 at 764.65
0.1%
Not planned
15 Aug 2025
Montarce Lucas EVP & CFO
Bought
$494.63K 715 at 691.79
5.1%
First buy on file
13 Aug 2025
Van Naarden Jacob EVP & Pres., Lilly Oncology
Bought
$647.36K 1,000 at 647.36
5.1%
First buy on file
13 Aug 2025
Alvarez Ralph Director · indirect
Bought
$500.47K 758 at 660.25
opened
First buy on file
12 Aug 2025
Ricks David A President, Chair, and CEO
Bought
$1.05M 1,632 at 644.77
0.3%
First buy on file
12 Aug 2025
Fyrwald J Erik Director
Bought 2×
$1.01M 1,565 at 642.33
2.1%
First buy on file
12 Aug 2025
Skovronsky Daniel EVP, CSO & Pres. LRL & LLY Imm
Bought
$634.41K 1,000 at 634.41
0.7%
First buy on file
12 Aug 2025
Bought
$75.02K 117 at 641.18
4.5%
First buy on file
8 Aug 2025
JACKSON JAMERE Director
Bought
$127.91K 200 at 639.56
2.2%
First buy on file
24 Jul 2025
Sold at will 6×
$225.42M 280,000 at 805.07
0.3%
Not planned
3 Mar 2025
Sold at will 13×
$204.33M 220,000 at 928.76
0.2%
Not planned
25 Feb 2025
Sold at will 12×
$203.19M 225,000 at 903.07
0.2%
Not planned
24 Feb 2025
Sold at will 15×
$1.65B 60,432 at 27,282.83
0.1%
Not planned
21 Feb 2025
Sold at will 17×
$87.79M 99,452 at 882.70
0.1%
Not planned
20 Feb 2025
Sold at will 4×
$12.89M 14,685 at 877.99
0.0%
Not planned
19 Feb 2025
Sold at will 4×
$8.77M 9,985 at 878.45
0.0%
Not planned
13 Feb 2025
Sold at will 7×
$31.18M 35,446 at 879.52
0.0%
Not planned
10 Feb 2025
Skovronsky Daniel EVP, CSO & Pres. LRL & LLY Imm
Sold at will 3×
$4.32M 5,000 at 863.21
4.1%
Not planned
Showing 1–50 of 123. Page 1 of 3 Older →